Not all patents are maintained through their full 20-year term. Maintenance fee payment rates vary significantly by technology sector, reflecting the commercial lifecycle of different technologies.
High-lapse sectors
Software & IT — Technology cycles are short; software patents often become commercially irrelevant before the 7.5-year fee window. Lapse rates are high, especially for companies acquired or restructured.
Consumer electronics — Product generations move fast. Patents protecting specific implementations are often abandoned as successor products supersede them.
Startups across all sectors — Cash-constrained companies frequently let non-core patents lapse during fundraising gaps or pivots.
Low-lapse sectors
Pharmaceuticals — Drug patents are maintained through full term, supported by patent term extensions for FDA delays. Lapse before natural expiry is rare.
Medical devices — Regulatory investment and product longevity make maintenance cost-effective.
Semiconductor core IP — Foundational process patents are maintained aggressively by major chip makers.
What to watch for
The most actionable lapses are core patents from companies that have been acquired, pivoted, gone bankrupt, or are in cost-cutting mode. PatentLapse monitors USPTO fee events and can alert you to lapses across any watchlist of patents — by assignee, technology class, or individual patent number.
Monitor any patent for maintenance fee windows and lapses — automatically
What percentage of patents lapse before natural expiry?
Studies suggest 50–60% of granted US patents are abandoned before their 20-year term, typically at one of the three maintenance fee windows.
Which technology sector has the highest patent lapse rate?
Software and IT patents have among the highest lapse rates, driven by short technology cycles and high startup activity. Consumer electronics is similarly high.
Do pharmaceutical patents lapse early?
Rarely. Pharmaceutical patents are almost always maintained through full term, and pharma companies frequently obtain patent term extensions for FDA approval delays.
Last updated: 2026-08-30 · Data: USPTO public domain ·
Not legal advice — consult a patent attorney before acting on this information.